Bergan T, Bjerke P E, Fausa O
Chemotherapy. 1981;27(4):233-8. doi: 10.1159/000237985.
Tablets of 500 mg metronidazole were given to 24 patients with intestinal diseases and to 10 healthy volunteers. The diagnoses included coeliac disease, ulcerative colitis, jejunoileal shunt, ileostomy, and Crohn's disease. Both normal subjects and patients exhibited considerable variation in serum metronidazole concentrations. This applied particularly to the patients who had somewhat slower absorption and later occurrence of serum peaks than did the normal subjects. No major deviation occurred within any of the diagnostic groups. All but the ileostomy patients exhibited a lag before apparent absorption. The individual peaks occurred after 1.5-2.0 h and was 12.7 +/- 2.1 microgram/ml in all disease groups, except the ileostomy patients who exhibited a mean of 16.2 microgram/ml. In the healthy subjects, the mean peak was 12.1 +/- 4.6 microgram/ml. A major finding was the observation that the patients as a group had a higher total area under the serum curves (AUC) than the volunteers. The AUC of normal volunteers was 108.1 microgram . h . ml-1 compared to 260.5 microgram . h. ml-1 in the patients with ileostomy and 147.6 microgram . h . ml-1 for the others. The higher AUC values in the ileostomy group were associated with longer serum half-life values. The serum half-life was 8.3 in the normals, 11.9 with ileostomy and 7.2 h in the remainder. The normal individuals and the patients with ulcerative colitis had higher rates of absorption, those with coeliac disease or ileostomy lower absorption rates than was found elsewhere. The relative volume of distribution (the distribution coefficient) was the same in the healthy individuals as in each patients group, except for the ileostomy patients. The total body clearance was 1.94 liters/h in ileostomy, 3.68 liters/h in the other patients, and 5.43 liters/h in the normal subjects.
给24例肠道疾病患者和10名健康志愿者服用500毫克甲硝唑片剂。诊断包括乳糜泻、溃疡性结肠炎、空肠回肠分流术、回肠造口术和克罗恩病。正常受试者和患者的血清甲硝唑浓度均有相当大的差异。这尤其适用于那些吸收稍慢且血清峰值出现时间比正常受试者晚的患者。在任何诊断组中均未出现重大偏差。除回肠造口术患者外,所有患者在明显吸收前均有延迟。个体峰值出现在1.5 - 2.0小时后,所有疾病组(回肠造口术患者除外,其平均值为16.2微克/毫升)的峰值为12.7±2.1微克/毫升。在健康受试者中,平均峰值为12.1±4.6微克/毫升。一个主要发现是观察到患者组的血清曲线下总面积(AUC)高于志愿者。正常志愿者的AUC为108.1微克·小时·毫升⁻¹,回肠造口术患者为260.5微克·小时·毫升⁻¹,其他患者为147.6微克·小时·毫升⁻¹。回肠造口术组较高的AUC值与较长的血清半衰期值相关。正常受试者的血清半衰期为8.3小时,回肠造口术患者为11.9小时,其余患者为7.2小时。正常个体和溃疡性结肠炎患者的吸收速率较高,乳糜泻或回肠造口术患者的吸收速率低于其他情况。除回肠造口术患者外,健康个体和各患者组的相对分布容积(分布系数)相同。回肠造口术患者的全身清除率为1.94升/小时,其他患者为3.68升/小时,正常受试者为5.43升/小时。